UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 17,899 Shares of West Pharmaceutical Services, Inc. $WST

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 2.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 884,865 shares of the medical instruments supplier’s stock after selling 17,899 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 1.26% of West Pharmaceutical Services worth $317,667,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Elyxium Wealth LLC acquired a new position in West Pharmaceutical Services during the fourth quarter valued at approximately $25,000. CYBER HORNET ETFs LLC acquired a new position in shares of West Pharmaceutical Services during the 2nd quarter worth approximately $25,000. Cornerstone Planning Group LLC raised its stake in shares of West Pharmaceutical Services by 90.9% during the 1st quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 50 shares in the last quarter. Bayban bought a new stake in shares of West Pharmaceutical Services during the 4th quarter worth approximately $27,000. Finally, Avalon Trust Co acquired a new stake in shares of West Pharmaceutical Services in the 2nd quarter valued at approximately $28,000. Institutional investors and hedge funds own 93.90% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on WST shares. TD Cowen restated a “buy” rating on shares of West Pharmaceutical Services in a report on Wednesday, July 15th. BNP Paribas Exane began coverage on shares of West Pharmaceutical Services in a research report on Monday, July 13th. They issued an “outperform” rating and a $447.00 price objective for the company. Morgan Stanley boosted their price objective on shares of West Pharmaceutical Services from $325.00 to $365.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 9th. Evercore reiterated an “outperform” rating and issued a $425.00 target price on shares of West Pharmaceutical Services in a research note on Monday, July 27th. Finally, Weiss Ratings raised West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $368.08.

West Pharmaceutical Services Stock Performance

Shares of NYSE WST opened at $341.43 on Tuesday. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.12. The firm has a market cap of $24.03 billion, a price-to-earnings ratio of 43.72, a P/E/G ratio of 2.36 and a beta of 1.15. The stock’s fifty day moving average price is $350.79 and its two-hundred day moving average price is $304.68. West Pharmaceutical Services, Inc. has a one year low of $223.83 and a one year high of $386.00.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.08 by $0.29. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The company had revenue of $872.30 million during the quarter, compared to analysts’ expectations of $839.98 million. During the same quarter in the previous year, the business posted $1.84 earnings per share. West Pharmaceutical Services’s quarterly revenue was up 13.8% on a year-over-year basis. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. On average, equities analysts forecast that West Pharmaceutical Services, Inc. will post 8.93 EPS for the current year.

West Pharmaceutical Services Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were issued a $0.22 dividend. The ex-dividend date of this dividend was Wednesday, July 29th. This represents a $0.88 dividend on an annualized basis and a yield of 0.3%. West Pharmaceutical Services’s payout ratio is currently 11.27%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.